PL3221349T3 - Humanizowane przeciwciała tau w chorobie Alzheimera - Google Patents

Humanizowane przeciwciała tau w chorobie Alzheimera

Info

Publication number
PL3221349T3
PL3221349T3 PL15837211T PL15837211T PL3221349T3 PL 3221349 T3 PL3221349 T3 PL 3221349T3 PL 15837211 T PL15837211 T PL 15837211T PL 15837211 T PL15837211 T PL 15837211T PL 3221349 T3 PL3221349 T3 PL 3221349T3
Authority
PL
Poland
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
PL15837211T
Other languages
English (en)
Polish (pl)
Inventor
Michal Novak
Eva Kontsekova
Branislav Kovacech
Rostislav SKRABANA
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of PL3221349T3 publication Critical patent/PL3221349T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
PL15837211T 2014-11-19 2015-11-18 Humanizowane przeciwciała tau w chorobie Alzheimera PL3221349T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease
EP15837211.0A EP3221349B1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (1)

Publication Number Publication Date
PL3221349T3 true PL3221349T3 (pl) 2021-05-17

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15837211T PL3221349T3 (pl) 2014-11-19 2015-11-18 Humanizowane przeciwciała tau w chorobie Alzheimera

Country Status (24)

Country Link
US (3) US10160799B2 (cg-RX-API-DMAC7.html)
EP (2) EP3221349B1 (cg-RX-API-DMAC7.html)
JP (3) JP6830061B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170126855A (cg-RX-API-DMAC7.html)
CN (1) CN107428820B (cg-RX-API-DMAC7.html)
AU (2) AU2015348012B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017010498A2 (cg-RX-API-DMAC7.html)
CA (1) CA2966964A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123746T1 (cg-RX-API-DMAC7.html)
DK (1) DK3221349T3 (cg-RX-API-DMAC7.html)
ES (1) ES2848376T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210124T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053239T2 (cg-RX-API-DMAC7.html)
IL (2) IL251921B (cg-RX-API-DMAC7.html)
LT (1) LT3221349T (cg-RX-API-DMAC7.html)
MX (2) MX388142B (cg-RX-API-DMAC7.html)
PL (1) PL3221349T3 (cg-RX-API-DMAC7.html)
PT (1) PT3221349T (cg-RX-API-DMAC7.html)
RS (1) RS61431B1 (cg-RX-API-DMAC7.html)
RU (2) RU2020126237A (cg-RX-API-DMAC7.html)
SG (1) SG11201703237VA (cg-RX-API-DMAC7.html)
SI (1) SI3221349T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100055T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016079597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016079597A1 (en) * 2014-11-19 2016-05-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
IL262726B2 (en) * 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
CN110418804A (zh) * 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
KR20200144551A (ko) 2018-03-28 2020-12-29 악손 뉴로사이언스 에스이 알츠하이머병을 검출하고 치료하는 항체-기반 방법
AU2019262220B2 (en) * 2018-05-03 2025-10-16 Washington University Methods of diagnosing and treating based on site-specific tau phosphorylation
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
AU2018446059A1 (en) * 2018-10-17 2021-05-20 The University Of Queensland Methods and compositions for treating tauopathies
EP3877410A4 (en) * 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
JP7780200B2 (ja) * 2019-08-13 2025-12-04 ワシントン・ユニバーシティ Ｍｔｂｒタウアイソフォームを検出する方法およびその使用
EP4028040A2 (en) 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
EP4028775A4 (en) 2019-09-10 2023-04-12 Washington University BLOOD-BASED TEST FOR DIAGNOSIS AND TREATMENT BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION
CN115066437A (zh) * 2019-12-12 2022-09-16 艾利妥 使用抗cd33抗体的方法
US20230201136A1 (en) * 2020-02-28 2023-06-29 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
EP4217063A4 (en) * 2020-09-22 2024-10-30 Kathleen E. Clarence-Smith PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS
CN113156134B (zh) * 2020-11-26 2024-01-23 江苏荃信生物医药股份有限公司 用于检测人白介素23的elisa试剂盒及检测方法
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250044781A (ko) * 2022-08-10 2025-04-01 주식회사 엔케이맥스 확장된 자연 살해 세포를 이용한 알츠하이머병 치료 방법
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JPH07509250A (ja) 1992-07-27 1995-10-12 アメリカ合衆国 血液脳バリヤーへのリポソームの標的化
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP3816111B2 (ja) 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
DE60028055D1 (de) 1999-09-09 2006-06-22 Max Planck Gesellschaft Screening nach inhibitoren von "gepaarten helikalen filamenten"
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1581186A2 (en) 2002-12-03 2005-10-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP1581203A1 (en) 2002-12-24 2005-10-05 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
PT2627672T (pt) * 2010-10-11 2018-11-16 Univ Zuerich Anticorpos anti-tau humanos
KR20210099167A (ko) 2011-09-19 2021-08-11 악손 뉴로사이언스 에스이 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단
KR102132041B1 (ko) * 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
WO2016079597A1 (en) * 2014-11-19 2016-05-26 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease

Also Published As

Publication number Publication date
RS61431B1 (sr) 2021-03-31
US11319363B2 (en) 2022-05-03
RU2730668C2 (ru) 2020-08-24
RU2017120688A3 (cg-RX-API-DMAC7.html) 2019-07-17
US10745469B2 (en) 2020-08-18
RU2020126237A (ru) 2020-12-01
RU2017120688A (ru) 2018-12-19
US20210009666A1 (en) 2021-01-14
EP3221349B1 (en) 2020-11-04
IL251921B (en) 2021-07-29
HRP20210124T1 (hr) 2021-03-19
EP3786182A1 (en) 2021-03-03
CN107428820B (zh) 2022-03-22
KR20170126855A (ko) 2017-11-20
CN107428820A (zh) 2017-12-01
SG11201703237VA (en) 2017-06-29
IL251921A0 (en) 2017-06-29
MX388142B (es) 2025-03-19
US10160799B2 (en) 2018-12-25
HUE053239T2 (hu) 2021-06-28
US20180142007A1 (en) 2018-05-24
DK3221349T3 (da) 2021-01-04
JP2021119774A (ja) 2021-08-19
JP6830061B2 (ja) 2021-02-17
WO2016079597A1 (en) 2016-05-26
PT3221349T (pt) 2021-01-21
AU2015348012B2 (en) 2020-07-02
MX2017006663A (es) 2017-08-21
ES2848376T3 (es) 2021-08-09
AU2020227007B2 (en) 2024-05-30
US20190169276A1 (en) 2019-06-06
SI3221349T1 (sl) 2021-02-26
AU2020227007A1 (en) 2020-09-17
SMT202100055T1 (it) 2021-03-15
WO2016079597A8 (en) 2020-07-02
BR112017010498A2 (pt) 2017-12-26
MX2021014367A (es) 2022-01-06
CY1123746T1 (el) 2022-05-27
HK1244495A1 (en) 2018-08-10
JP2018502558A (ja) 2018-02-01
JP2020141669A (ja) 2020-09-10
LT3221349T (lt) 2021-02-10
CA2966964A1 (en) 2016-05-26
IL284250A (en) 2021-07-29
JP6864763B2 (ja) 2021-04-28
EP3221349A1 (en) 2017-09-27
AU2015348012A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
IL285722A (en) Methods for treating Alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL252929A0 (en) Anti-acth antibodies from humans and their use
GB201610044D0 (en) Antibodies
IL251837A0 (en) Anti-endoglin antibodies and their uses
PL3311171T3 (pl) Epitop przeciwciała
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201616699D0 (en) Antibodies
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201603291D0 (en) Antibodies
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL267271A (en) Antibodies against il-5
PT3484921T (pt) Anticorpos anti-il-22r
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL260083A (en) Antibody against myl9
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201414038D0 (en) Alzheimer's disease
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies